|
|
The overwhelming case for LDL-C lowering
|
|
|
|
4S Primary Endpoint: Total Mortality
|
|
|
|
HPS: Effects of Simvastatin
|
|
|
|
ASCOT-LLA
|
|
|
|
CARDS
|
|
|
|
CTT Collaboration
|
|
|
|
Cholesterol Trialist Collaboration
|
|
|
|
Only high dose statins
|
|
|
|
All-Cause Death or Major CV Events in
|
|
|
|
Is there benefit from an LDL of
|
|
|
|
Cholesterol Trialist Collaboration
|
|
|
|
Meta-Analysis of Intensive Statin Therapy
|
|
|
|
Meta-Analysis of Intensive Statin Therapy
|
|
|
|
PROVE IT-TIMI 22
|
|
|
|
TNT: Incidence of First Major
|
|
|
|
JUPITER
|
|
|
|
JUPITER
|
|
|
|
JUPITER
|
|
|
|
Event rates by achieved LDL-C in trials
|
|
|
|
PROVE IT Safety Result
|
|
|
|
Adverse Event Profiles TNT
|
|
|
|
CTT Lancet 2012
|
|
|
|
Statins increase risk of Dysglycaemia
|
|
|
|
Statins and DYSGLYCAEMIA vs CVD Risk
|
|
|
|
New-Onset T2DM
|
|
|
|
Evidence for Clinical Benefit
|
|
|
|
Summary
|
|
Download presentations as PPT (PPTX 1MB)
Share this page with your colleagues and friends: